Colon Preparation With 2L PEG in Combination With Lubiprostone vs 4L PEG

August 10, 2021 updated by: Rajavithi Hospital

Comparison of Colon Preparation With 2-Litre Polyethylene Glycol (PEG) Split-dose in Combination With Lubiprostone Versus 4-Litre Polyethylene Glycol (PEG) Split-dose: a Randomized Controlled Trial

Colonoscopy is the current standard method for examination of the colon. Bowel cleansing prior to colonoscopy is the essential prerequisite to ensure complete mucosal visualization and lesion identification.(1,2) Suboptimal preparations are associated with missed diagnoses, longer procedure times and increased costs related to the repeat procedures and shortened intervals between procedures.(3-5) Inadequate preparations have been noted in around 25 % cases in the US.(4,6) This has been attributed primarily to poor patient tolerance to the standard colon preparations.

Osmotically balanced polyethylene glycol (PEG) electrolyte bowel lavage solutions were introduced in 1980.(7) These PEG based solutions are the most commonly used bowel preparations today.(7) They have high efficacy, are safe and are associated with minimal fluid and electrolyte imbalance. However the major drawback of these preparations is the taste and the large volumes required with associated nausea, cramping and vomiting.(8) This often results in poor compliance and tolerance with resultant poor preparation and improper visualization. A pooled analysis of 15 trials found that at least 29 % of patients were unable to complete their PEG solution.(9) Lubiprostone (LB) is a locally acting selective Type 2 chloride channel activator which causes intestinal fluid secretion. This results in increased softened stool and increased intestinal transit without the loss of either net intravascular fluid or electrolytes.(10) Peak plasma levels occur approximately 1.14 h after oral administration of a single 24 microgram dose, and the half-life of lubiprostone (t½) has been estimated at approximately 3 h.(11,12) LB is currently approved for the treatment of chronic idiopathic constipation and is generally well tolerated with an excellent side effect profile. Even long term usage has not shown clinically significant changes in electrolyte levels.(10,13) Our hypothesis was that administration of LB in addition to low volume (2-L) split-dose PEG would improve the adequacy of the bowel preparation as comparable as standard 4-L split-dose PEG regimens. Additionally, it could improve patient tolerability and decreased side effects related to the large volume of PEG regimens. Accordingly, we conducted this prospective, single-blind, randomized controlled trial.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Study design:

This was a single center prospective, single-blind, randomized controlled trial to compare the quality of bowel preparation using 2-L PEG with LB vs. 4-L PEG conducted from September 2019 to June 2020 at Department of Medicine, Rajavithi Hospital, a tertiary referral center in Bangkok, Thailand. It was performed in accordance with the clinical principles laid down in the Declaration of Helsinki and informed consent was obtained from all the participants before their enrollment. The study protocol was reviewed and approved by the ethics committee of Rajavithi Hospital. Recruitment, enrollment, randomization, withdrawal, and completion were done according to the consort guidelines.

Bowel preparation method:

PEG used in the present study was Niflec® (Meiji, Japan), which composed of macrogol 4,000 plus electrolytes (sodium sulfate, sodium hydrogen carbonate, sodium chloride, and potassium chloride) and is taken by diluting one sachet into 2-L of plain water. The participants were instructed to take 250 mL every 15 min untill the entire solution was consumed. In cases of 4-L split-dosage, half dose preparation started in the evening of the pre-procedure day at about 8.00 to 10.00 pm and the remaining dose was given in the morning at about 5.00 to 7.00 am on the procedure day. In cases of 2-L split-dosage, half dose preparation started in the evening of the pre-procedure day at about 8.00 to 9.00 pm and the remaining dose was given in the morning at about 5.00 to 6.00 am on the procedure day. And these patients, one 24 mcg tablet of LB was given 2 hours before PEG ingestion (at 6.00 pm of the pre-procedure day).

Dietary advice was given to all patients. Consumption of fruit, legumes, or vegetable was forbidden 2 days before the procedure. On the day before colonoscopy patients had a light breakfast and lunch, but a liquid dinner (clear soup). Solid food was not allowed at the start of the bowel preparation phase. All patients were instructed to fast from midnight before procedure day, but some anti-hypertensive drugs and minimal plain water were permitted.

Randomization:

All participants attended an informational session before colonoscopy where the participants were counseled about the nature of the study and written informed consent was obtained. The research coordinator used a computer to generate a randomization table with blocks of 8. Allocation concealment was maintained through the use of consecutively numbered sealed envelopes. The allocation ratio was 1:1 in 2-L PEG with LB (Group A) or 4-L PEG (Group B).

An endoscopy nurse assigned the participants to their group and instructed the participants on the proper use of their assigned bowel preparation method as well as dietary advice. Gastroenterologists and investigators were blinded to the allocation groups. The participants were given a questionnaire measured the tolerability and side effects of the bowel preparation regimen, to be completed once their bowel preparation was finished and before coming to the hospital for the colonoscopy.

Colonoscopy:

All colonoscopies were performed by 3 experienced gastroenterologists (minimum experience of 1000 procedures; Apichet Sirinawasatien, Kanokpoj Chanpiwat, and Tanyaporn Chantarojanasiri) at the Rajavithi Hospital. A standard protocol for insertion, withdrawal, and observation was followed. All colonoscopies were performed using video colonoscopes (CF 180, Olympus, Japan) under moderate sedation.

The colon segment including the rectum and extending up to the splenic flexure was termed as left colon; the segment between splenic flexure and hepatic flexure was termed transverse colon; while colon segment proximal to hepatic flexure, including the cecum was termed right colon for the purpose of this study. A complete colonoscopy was defined as reaching the cecum determined by the visualization and documentation of the ileocecal valve and appendiceal orifice. Failed colonoscopy was defined as endoscope could not reach ileocecal valve and cecum. Overall procedure times was the times between the endoscope enter and withdraw from the anus.

During the insertion of the scope, two representative pictures were taken from each of these three segments to document the colon preparation. An early colonoscopy was defined as a procedure initiated during 8-11 am while those started after 11 am were considered the late procedure.

Colon cleansing scale:

The investigators used Boston bowel preparation scale (BBPS) score to evaluate the adequacy of the preparation. Each colonic segment was graded from 0 (solid stools) to 3 (no residual staining). The aggregate score was obtained by adding the score for all 3 segments, thus resulting in a score between 0 and 9. A score ≤4 was considered a poor colon preparation, resulting in a recommendation for a repeat procedure. A score of 8-9 was considered excellent preparation while a score of 5-7 was considered adequate preparation.

The colon preparation was graded by analyzing photo documentation obtained during a colonoscopy by three gastroenterologists (AS, KC, and TC) after the procedure finished. The mean BBPS score of each patient was calculated and recorded the result on a separate standardized form.

Sample size calculation and statistical analysis:

Descriptive statistics were used for baseline characteristics. The Boston bowel preparation scale produces data that are approximately normally distributed. Two-group ANOVA was used to assess for the presence of group differences in the preparation scores while accounting for procedure time (early versus late). The proportion of adequate bowel preparation in each group was compared with a chi-square statistic. The secondary endpoints of tolerability and side effects were assessed using the Mann-Whitney U test.

The sample size was calculated using two independent means formula (two-tailed test) based on data from a previous study in 2008,(16) in which the patient mean overall symptom questionnaire ratings of the PEG plus LB group was 3.7±1 compared to 3.2±1.1 in the controlled group (p = 0.003). The minimum required number of participants was calculated at 70 in each group in order to detect a significant association with 80% power (β =0.20) and a 5% probability of type I error (2-sided) (α =0.05).

Study Type

Interventional

Enrollment (Actual)

140

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Thailand
      • Bangkok, Thailand, 10400
        • Rajavithi Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • All patients between the age of 18 and 75 years with an appropriate indication for elective colonoscopy were considered eligible.

Exclusion Criteria:

  • We excluded patients who (i) suspected gastroparesis, gastric outlet or bowel obstruction; (ii) had a previous history of any gastrointestinal surgery apart from an appendectomy and cholecystectomy; (iii) had severe cardiac or pulmonary disease (American Society of Anesthesiologists physical status class 3 or 4), severe renal failure (creatinine clearance <30 mL/min), decompensated liver cirrhosis or severe systemic illness; (iv) had a compromised swallowing reflex or impaired mental status; (v) were in a state of pregnancy or lactating; (vi) were hypersensitive or allergic to PEG or LB; or (vii) had a history of previous failure of adequate bowel preparation for colonoscopy.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: 2-L PEG with LB

PEG used in the present study was Niflec® (Meiji, Japan), which composed of macrogol 4,000 plus electrolytes (sodium sulfate, sodium hydrogen carbonate, sodium chloride, and potassium chloride) and is taken by diluting one sachet into 2-L of plain water. The patients were instructed to take 250 mL every 15 min untill the entire solution was consumed.

In this group (2-L PEG), half dose preparation started in the evening of the pre-procedure day at about 8.00 to 9.00 pm and the remaining dose was given in the morning at about 5.00 to 6.00 am on the procedure day. And these patients, one 24 mcg tablet of LB was given 2 hours before PEG ingestion (at 6.00 pm of the pre-procedure day).
Drug: polyethylene glycol in combination with lubiprostone
2-litre polyethylene glycol split-dose in combination with one 24 mcg tablet of lubiprostone
Other Names:
  • NIFLEC in combination with Amitiza
Active Comparator: 4-L PEG
In this group (4-L PEG), half dose preparation started in the evening of the pre-procedure day at about 8.00 to 10.00 pm and the remaining dose was given in the morning at about 5.00 to 7.00 am on the procedure day.
Drug: polyethylene glycol alone
4-litre polyethylene glycol split-dose
Other Names:
  • NIFLEC alone

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
the degree of colon cleansing
Time Frame: up to 7 months

We used Boston bowel preparation scale (BBPS) score to evaluate the adequacy of the preparation. Each colonic segment was graded from 0 (solid stools) to 3 (no residual staining). The aggregate score was obtained by adding the score for all 3 segments, thus resulting in a score between 0 and 9. A score ≤4 was considered a poor colon preparation, resulting in a recommendation for a repeat procedure. A score of 8-9 was considered excellent preparation while a score of 5-7 was considered adequate preparation.

The colon preparation was graded by analyzing photo documentation obtained during a colonoscopy by three gastroenterologists (AS, KJ, and TC) after the procedure finished. The mean BBPS score of each patient was calculated and recorded the result on a separate standardized form.
up to 7 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
patient's tolerability
Time Frame: up to 7 months
The patient's tolerability on taking the bowel preparation was evaluated with a 10-cm visual analog scale which 10 means excellent and 0 means very poor.
up to 7 months
adverse events related to bowel preparation
Time Frame: up to 7 months
Any adverse events related to bowel preparation (nausea, vomiting, bloating, abdominal pain, dizziness, etc.) were recorded by the endoscopy nurse.
up to 7 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Rajavithi Hospital

Investigators

  • Principal Investigator: Apichet Sirinawasatien, MD, Rajavithi Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 1, 2019

Primary Completion (Actual)

June 30, 2021

Study Completion (Actual)

July 30, 2021

Study Registration Dates

First Submitted

October 14, 2019

First Submitted That Met QC Criteria

October 22, 2019

First Posted (Actual)

October 24, 2019

Study Record Updates

Last Update Posted (Actual)

August 11, 2021

Last Update Submitted That Met QC Criteria

August 10, 2021

Last Verified

August 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 106/2562

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Indication for Modification of Patient Status (Diagnosis)

Clinical Trials on polyethylene glycol in combination with lubiprostone

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Liberia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe